Efficacy and safety of rosuvastatin in the management of dyslipidemia

References

• BaigentCKeechAKearneyPMCholesterol Treatment Trialists’ (CTT) CollaboratorsEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet20053661267127816214597
   PubMed Web of Science ®Google Scholar
• RosensonRSRosuvastatin: a new inhibitor of HMG-coA reduc-tase for the treatment of dyslipidemiaExp Rev Cardiovasc Ther20031495505
   PubMedGoogle Scholar
• McKenneyJMEfficacy and safety of rosuvastatin in treatment of dyslipidemiaAm J Health Syst Pharm2005621033104715901588
   PubMed Web of Science ®Google Scholar
• SEARCH Collaborative GroupLinkEParishSArmitageJSLCO1B1 variants and statin-induced myopathy – a genomewide studyN Engl J Med200835978979918650507
   PubMed Web of Science ®Google Scholar
• NeuvonenPJNiemiMBackmanJTDrug interactions with lipid-lowering drugs: mechanisms and clinical relevanceClin Pharmacol Ther20068056558117178259
   PubMed Web of Science ®Google Scholar
• BottorffMBStatin safety and drug interactions: clinical implicationsAm J Cardiol20069727C31C
   PubMed Web of Science ®Google Scholar
• SchneckDWBirminghamBKZalikowskiJAThe effect of gemfibrozil on the pharmacokinetics of rosuvastatinClin Pharmacol Ther20047545546315116058
   PubMed Web of Science ®Google Scholar
• SimonsonSGRazaAMartinPDRosuvastatin pharmacokinetics in heart transplant recipients administered anantirejection regimen including cyclosporineClin Pharmacol Ther20047616717715289793
   PubMed Web of Science ®Google Scholar
• MerzTFullerSHElevated serum transaminase levels resulting from concomitant use of rosuvastatin and amiodaroneAm J Health Syst Pharm2007641818182117724362
   PubMed Web of Science ®Google Scholar
• ShepherdJHunninghakeDBSteinEASafety of rosuvastatinAm J Cardiol20049488288815464670
   PubMed Web of Science ®Google Scholar
• JacobsonTAToward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgiaMayo Clin Proc20088368770018533086
   PubMed Web of Science ®Google Scholar
• MarieIDelafenêtreHMassyNThuillezCNobletCNetwork of the French Pharmacovigilance Centers. Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990–2005 and review of the literatureArthritis Rheum20085936737218311771
   PubMed Web of Science ®Google Scholar
• JacobsonTAThe safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be loweredMayo Clin Proc2006811225123116970219
   PubMed Web of Science ®Google Scholar
• LaRosaJCLow-density lipoprotein cholesterol reduction: the end is more important than the meansAm J Cardiol200710024024217631077
   PubMed Web of Science ®Google Scholar
• McKenneyJMPharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risksAm J Cardiol20059660E66E
   PubMed Web of Science ®Google Scholar
• SchwartzGGBologneseMATremblayBPEfficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trialAm Heart J2004148e415215813
   PubMed Web of Science ®Google Scholar
• JonesPHHunninghakeDBFerdinandKCStatin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study GroupEffects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trialClin Ther2004261388139915531001
   PubMed Web of Science ®Google Scholar
• BallantyneCMRaichlenJSCainVAStatin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trialJ Am Coll Cardiol20085262663218702965
   PubMed Web of Science ®Google Scholar
• SchusterHBarterPJStenderSEffective Reductions in Cholesterol Using Rosuvastatin Therapy I study groupEffects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) studyAm Heart J200414770571315077101
   PubMed Web of Science ®Google Scholar
• SteinEAStruttKSouthworthHDigglePJMillerEHeFH Study GroupComparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemiaAm J Cardiol2003921287129314636905
   PubMed Web of Science ®Google Scholar
• SteinEAAmerenaJBallantyneCMLong-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemiaAm J Cardiol20071001387139617950795
   PubMed Web of Science ®Google Scholar
• DeedwaniaPCHunninghakeDBBaysHEJonesPHCainVABlasettoJWSTELLAR Study GroupEffects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndromeAm J Cardiol20059536036615670545
   PubMed Web of Science ®Google Scholar
• OoiEMWattsGFNestelPJSviridovDHoangABarrettPHDose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndromeJ Clin Endocrinol Metab20089343043718029469
   PubMedGoogle Scholar
• AsztalosBFLe MaulfFDallalGEComparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteinsAm J Cardiol20079968168517317371
   PubMed Web of Science ®Google Scholar
• LamendolaCAbbasiFChuJWComparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemiaAm J Cardiol20059518919315642550
   PubMed Web of Science ®Google Scholar
• AiMOtokozawaSAsztalosBFEffects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levelsAm J Cardiol200810131531818237592
   PubMed Web of Science ®Google Scholar
• BetteridgeDJGibsonJMSagerPTComparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (<70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study)Am J Cardiol20071001245124817920365
   PubMed Web of Science ®Google Scholar
• SerebruanyVLMillerMPokovANEffect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study)Am J Cardiol2006971332133616635606
   PubMed Web of Science ®Google Scholar
• InsullWJrGhaliJKHassmanDRSOLAR Study GroupAchieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trialMayo Clin Proc20078254355017493418
   PubMed Web of Science ®Google Scholar
• MillerPSSmithDGJonesPA Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (an US Analysis of the STELLAR Trial)Am J Cardiol2005951314131915904635
   PubMedGoogle Scholar
• BallantyneCMBertolamiMHernandez GarciaHRAchieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY) IIAm Heart J2006151975.e1e916644314
   PubMed Web of Science ®Google Scholar
• BallantyneCMWeissRMoccettiTEXPLORER Study InvestigatorsEfficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)Am J Cardiol20079967368017317370
   PubMed Web of Science ®Google Scholar
• CrouseJR3rdRaichlenJSRileyWAMETEOR Study GroupEffect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR TrialJAMA20072971344135317384434
   PubMed Web of Science ®Google Scholar
• UnderhillHRYuanCZhaoXQEffect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trialAm Heart J2008155584.e1e818294500
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJSipahiIASTEROID InvestigatorsJAMA20062951556156516533939
   PubMed Web of Science ®Google Scholar
• BallantyneCMRaichlenJSNichollsSJASTEROID InvestigatorsEffect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burdenCirculation20081172458246618378607
   PubMed Web of Science ®Google Scholar
• VidtDGHarrisSMcTaggartFDitmarschMSagerPTSorofJMEffect of short-term rosuvastatin treatment on estimated glomerular filtration rateAm J Cardiol2006971602160616728222
   PubMed Web of Science ®Google Scholar
• LuTMDingYALeuHBYinWHSheuWHChuKMEffect of rosuvastatin on plasma levels of asymmetric Dimethylarginine in patients with hypercholesterolemiaAm J Cardiol20049415716115246890
   PubMed Web of Science ®Google Scholar
• GottoAMJrReview of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatinAm J Cardiol20059634F38F
   PubMed Web of Science ®Google Scholar
• YunKHJeongMHOhSKThe beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndromeInt J Cardiol2008813 [Epub ahead of print]
   Google Scholar
• GottoAMJrRole of C-reactive protein in coronary risk reduction: focus on primary preventionAm J Cardiol20079971872517317380
   PubMed Web of Science ®Google Scholar
• MoraSRidkerPMJustification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) can C-reactive protein be used to target statin therapy in primary preventionAm J Cardiol20069733A341A
   PubMed Web of Science ®Google Scholar
• RidkerPMFonsecaFAGenestJJUPITER Trial Study GroupBaseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive proteinAm J Cardiol20071001659166418036365
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFAthe JUPITER Study GroupRosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. 1N Engl J Med200835922195220718997196
   PubMedGoogle Scholar
• BaigentCKeechAKearneyPMCholesterol Treatment Trial-ists’ (CTT) CollaboratorsEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet20053661267127816214597
   PubMed Web of Science ®Google Scholar
• LawMRWaldNJRudnickaARQuantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ2003326142312829554
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) CollaboratorsKearneyPMBlackwellLCollinsREfficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysisLancet200837111712518191683
   PubMed Web of Science ®Google Scholar
• HausenloyDJYellonDMTargeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levelsHeart20089470671418480348
   PubMed Web of Science ®Google Scholar
• RubbaPOrphans of best preventionNutr Metab Cardiovasc Dis20071748348517628457
   PubMedGoogle Scholar